Granted Patent
B2
US 12,599,607 · App. 18/778,226 · Granted Apr 14, 2026
Pharmaceutical compositions comprising timolol
Inventors:
Frank Löscher (Schriesheim, DE); Sonja Krösser (Heidelberg, DE); Diana Strehl (Heidelberg, DE); Bernhard Hauptmeier (Schriesheim, DE); Kirsten Eickhoff (Aschaffenburg, DE)
Assignee:
NOVALIQ GMBH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to pharmaceutical composition comprising the beta 1 (β 1 )-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.
Claims (21)
1 . A pharmaceutical composition consisting of particles of timolol maleate and a liquid vehicle; wherein the particles consist of the timolol maleate, and wherein the particles are suspended in the liquid vehicle; wherein the liquid vehicle consists essentially of 1-perfluorohexyloctane and optionally a co-solvent; wherein at least 90% of the suspended particles of the timolol maleate have a size of not more than about 20 μm; wherein the concentration of the timolol maleate in the pharmaceutical composition corresponds to about 0.5% (w/v) of timolol, measured as the free base; and wherein the composition is formulated for topical ophthalmic administration.
2 . The pharmaceutical composition according to claim 1 , wherein the liquid vehicle further comprises the co-solvent.
3 . The pharmaceutical composition according to claim 1 , wherein the liquid vehicle consists essentially of the 1-perfluorohexyloctane.
4 . The pharmaceutical composition of claim 1 , wherein at least about 90% of the suspended particles of the timolol maleate have a size of not more than about 15 μm.
5 . The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition provides a dose volume per eye of from about 10 to about 12 μl which comprises about 55 μg timolol, measured as the free base.
6 . A method for the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, in a patient in need thereof, comprising administering to said patient a pharmaceutical composition according to claim 1 , wherein the composition is topically administered to the eye of the patient at a single dose of about 55 μg timolol, measured as the free base, per eye.
7 . The method according to claim 6 , wherein the pharmaceutical composition is administered to the eye of the patient up to four times daily.
8 . The method according to claim 6 , wherein the pharmaceutical composition is administered to the eye of the patient two times daily or once daily.
9 . The method according to claim 6 , wherein the pharmaceutical composition is administered in a dose volume per eye of from about 10 to about 12 μl.
10 . The method according to claim 6 , wherein the liquid vehicle further comprises the co-solvent.
11 . The method according to claim 6 , wherein the liquid vehicle essentially consists of the 1-perfluorohexyloctane.
12 . The method according to claim 6 , wherein the pharmaceutical composition is topically administered to the eye of the patient at a single dose of 55 μg timolol, measured as the free base, per eye.
13 . The method according to claim 6 , wherein the pharmaceutical composition is administered in a dose volume per eye of from about 11 μl.
14 . The method according to claim 11 , wherein the pharmaceutical composition is topically administered one time daily to the eye of the patient at a single dose of 55 μg timolol, measured as the free base, per eye.
15 . The method according to claim 11 , wherein the pharmaceutical composition is topically administered two times daily to the eye of the patient at a single dose of 11 μl per eye.
16 . The method according to claim 6 , wherein the pharmaceutical composition is free of water and free of a preservative.
17 . The method according to claim 6 , wherein at least about 90% of the suspended particles of timolol maleate have a size of not more than about 10 μm.
18 . The method according to claim 6 , wherein at least about 90% of the suspended particles of timolol maleate have a size of not more than about 15 μm after three weeks of storage at room temperature.
19 . The composition according to claim 1 , wherein the liquid vehicle consists essentially of at least 99.5% (w/w) 1-perfluorohexyloctane, with respect to the total weight of the liquid vehicle.
20 . The method according to claim 16 , wherein the pharmaceutical composition is a preservative-free ophthalmic composition, that is provided in a microbiologically stable multi-dose or single dose format.
21 . The method according to claim 16 , wherein the method comprises the step of redispersing the particles of timolol maleate by gently shaking the container holding the composition before topically administering the composition to the eye.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 30, 2024
From: LÖSCHER, FRANK; KRÖSSER, SONJA; STREHL, DIANA; HAUPTMEIER, BERNHARD; EICKHOFF, KIRSTEN
To: NOVALIQ GMBH
Reel/Frame 068736/0675 →
Priority Claims (2)
EP 18164563
· Mar 28, 2018
· regional
EP 18185436
· Jul 25, 2018
· regional
Continuity (2)
Continuation
17041758
References Cited (281)
US 2616927A
· Kauck et al.
· 1952
[cited by applicant]
US 4452818A
· Haidt
· 1984
[cited by applicant]
US 5077036A
· Long
· 1991
[cited by applicant]
US 5326566A
· Parab
· 1994
[cited by applicant]
US 5336175A
· Mames
· 1994
[cited by applicant]
US 5370313A
· Beard
· 1994
[cited by applicant]
US 5518731A
· Meadows
· 1996
[cited by applicant]
US 5578020A
· Mosley
· 1996
[cited by applicant]
US 5667809A
· Trevino et al.
· 1997
[cited by applicant]
US 5874469A
· Maniar et al.
· 1999
[cited by applicant]
US 5874481A
· Weers et al.
· 1999
[cited by applicant]
US 5904933A
· Riess et al.
· 1999
[cited by applicant]
US 5980936A
· Krafft et al.
· 1999
[cited by applicant]
US 5981607A
· Ding
· 1999
[cited by applicant]
US 6042845A
· Sun et al.
· 2000
[cited by applicant]
US 6060085A
· Osborne
· 2000
[cited by applicant]
US 6113919A
· Reiss et al.
· 2000
[cited by applicant]
US 6140374A
· May et al.
· 2000
[cited by applicant]
US 6159977A
· Reeves
· 2000
[cited by applicant]
US 6177477B1
· George et al.
· 2001
[cited by applicant]
US 6197323B1
· Georgieff
· 2001
[cited by applicant]
US 6224887B1
· Samour et al.
· 2001
[cited by applicant]
US 6262126B1
· Meinert et al.
· 2001
[cited by applicant]
US 6264990B1
· Knepp et al.
· 2001
[cited by applicant]
US 6294563B1
· Garst
· 2001
[cited by applicant]
US 6335335B2
· Higashiyama
· 2002
[cited by applicant]
US 6372243B2
· Kobuch
· 2002
[cited by applicant]
US 6391879B1
· Reeves
· 2002
[cited by applicant]
US 6399087B1
· Zhang et al.
· 2002
[cited by applicant]
US 6458376B1
· Meadows
· 2002
[cited by applicant]
US 6486212B2
· Meinert
· 2002
[cited by applicant]
US 6489367B1
· Meinert
· 2002
[cited by applicant]
US 6528086B2
· Zhang
· 2003
[cited by applicant]
US 6730328B2
· Maskiewicz et al.
· 2004
[cited by applicant]
US 7001607B1
· Menz et al.
· 2006
[cited by applicant]
US 7026359B1
· Gross
· 2006
[cited by applicant]
US 7041705B2
· Mishra et al.
· 2006
[cited by applicant]
US 7063241B2
· Spada et al.
· 2006
[cited by applicant]
US 7074827B2
· Ueno
· 2006
[cited by applicant]
US 7258869B1
· Berry et al.
· 2007
[cited by applicant]
US 7687455B2
· Bonnet et al.
· 2010
[cited by applicant]
US 7740875B2
· Dechow
· 2010
[cited by applicant]
US 7776349B2
· Dechow et al.
· 2010
[cited by applicant]
US 8029977B2
· Meinert
· 2011
[cited by applicant]
US 8222292B2
· Goskonda et al.
· 2012
[cited by applicant]
US 8328775B2
· Gokhale et al.
· 2012
[cited by applicant]
US 8470873B2
· Chen et al.
· 2013
[cited by applicant]
US 8492334B2
· Lavik et al.
· 2013
[cited by applicant]
US 8501800B2
· Bowman et al.
· 2013
[cited by applicant]
US 8614178B2
· Theisinger et al.
· 2013
[cited by applicant]
US 8618093B2
· Chen et al.
· 2013
[cited by applicant]
US 8748425B2
· Chang et al.
· 2014
[cited by applicant]
US 8759404B2
· Daftary et al.
· 2014
[cited by applicant]
US 8772337B2
· Pilotaz et al.
· 2014
[cited by applicant]
US 8796340B2
· Theisinger et al.
· 2014
[cited by applicant]
US 8916157B2
· Krause et al.
· 2014
[cited by applicant]
US 8986738B2
· Meinert
· 2015
[cited by applicant]
US 9005626B2
· Seigfried
· 2015
[cited by applicant]
US 9023898B2
· Wong et al.
· 2015
[cited by applicant]
US 9241900B2
· Wilson
· 2016
[cited by applicant]
US 9308262B2
· Günther et al.
· 2016
[cited by applicant]
US 9757459B2
· Theisinger et al.
· 2017
[cited by applicant]
US 9757460B2
· Günther et al.
· 2017
[cited by applicant]
US 9770508B2
· Günther et al.
· 2017
[cited by applicant]
US 9968678B2
· Theisinger et al.
· 2018
[cited by applicant]
US RE50060E
· Graf et al.
· 2024
[cited by applicant]
US 20020004063A1
· Zhang
· 2002
[cited by applicant]
US 20020128527A1
· Meinert
· 2002
[cited by applicant]
US 20020198266A1
· Meinert
· 2002
[cited by applicant]
US 20030018044A1
· Peyman
· 2003
[cited by applicant]
US 20030027833A1
· Cleary et al.
· 2003
[cited by applicant]
US 20030170194A1
· Piotrowiak
· 2003
[cited by applicant]
US 20040044045A1
· Burk
· 2004
[cited by applicant]
US 20040082660A1
· Ueno
· 2004
[cited by applicant]
US 20040101551A1
· Selzer
· 2004
[cited by applicant]
US 20040265362A1
· Susilo
· 2004
[cited by applicant]
US 20040266702A1
· Dawson et al.
· 2004
[cited by applicant]
US 20050075407A1
· Tamarkin et al.
· 2005
[cited by applicant]
US 20050079210A1
· Gupta
· 2005
[cited by applicant]
US 20050175541A1
· Lanza et al.
· 2005
[cited by applicant]
US 20050274744A1
· Spada et al.
· 2005
[cited by applicant]
US 20050288196A1
· Horn
· 2005
[cited by applicant]
US 20060009522A1
· Dana et al.
· 2006
[cited by applicant]
US 20060153905A1
· Carrara et al.
· 2006
[cited by applicant]
US 20070238732A1
· Graham et al.
· 2007
[cited by applicant]
US 20080019926A1
· Krafft et al.
· 2008
[cited by applicant]
US 20080050335A1
· Faour et al.
· 2008
[cited by applicant]
US 20080089923A1
· Burkstrand et al.
· 2008
[cited by applicant]
US 20080153909A1
· Dana et al.
· 2008
[cited by applicant]
US 20080207537A1
· Turner et al.
· 2008
[cited by applicant]
US 20080234389A1
· Mecozzi et al.
· 2008
[cited by applicant]
US 20080254106A1
· Bell
· 2008
[cited by applicant]
US 20080260656A1
· Mallard
· 2008
[cited by applicant]
US 20090149546A1
· Chang
· 2009
[cited by applicant]
US 20090169601A1
· Koch et al.
· 2009
[cited by applicant]
US 20090226875A1
· Meinert
· 2009
[cited by applicant]
US 20100006600A1
· Dascanio
· 2010
[cited by applicant]
US 20100008996A1
· Meinert
· 2010
[cited by applicant]
US 20100016814A1
· Gokhale et al.
· 2010
[cited by applicant]
US 20100189765A1
· Erickson et al.
· 2010
[cited by applicant]
US 20100226997A1
· Bowman et al.
· 2010
[cited by applicant]
US 20100261646A1
· Lavik et al.
· 2010
[cited by applicant]
US 20100274215A1
· Wong et al.
· 2010
[cited by applicant]
US 20110223208A1
· Hill et al.
· 2011
[cited by applicant]
US 20110269704A1
· Seigfried
· 2011
[cited by applicant]
US 20120010280A1
· Aleo et al.
· 2012
[cited by applicant]
US 20120095097A1
· Tabuchi et al.
· 2012
[cited by applicant]
US 20120238639A1
· Theisinger et al.
· 2012
[cited by applicant]
US 20120244177A1
· Theisinger et al.
· 2012
[cited by applicant]
US 20130011484A1
· Bevier
· 2013
[cited by applicant]
US 20130046014A1
· Theisinger
· 2013
[cited by applicant]
US 20130084250A1
· Hagedorn et al.
· 2013
[cited by applicant]
US 20130266652A1
· Theisinger et al.
· 2013
[cited by applicant]
US 20130303473A1
· Wilson
· 2013
[cited by applicant]
US 20130336557A1
· Cruzat et al.
· 2013
[cited by applicant]
US 20140004197A1
· Theisinger et al.
· 2014
[cited by applicant]
US 20140100180A1
· Günther et al.
· 2014
[cited by applicant]
US 20140140942A1
· Günther et al.
· 2014
[cited by applicant]
US 20140186350A1
· Ghosh et al.
· 2014
[cited by applicant]
US 20140369993A1
· Günther et al.
· 2014
[cited by applicant]
US 20150045282A1
· Elsohly et al.
· 2015
[cited by applicant]
US 20150224064A1
· Günther et al.
· 2015
[cited by applicant]
US 20150238605A1
· Günther et al.
· 2015
[cited by applicant]
US 20160000941A1
· Keller et al.
· 2016
[cited by applicant]
US 20160101178A1
· Wilson
· 2016
[cited by examiner]
US 20160159902A1
· Günther et al.
· 2016
[cited by applicant]
US 20160243189A1
· Gu et al.
· 2016
[cited by applicant]
US 20160303031A1
· El Achkar et al.
· 2016
[cited by applicant]
US 20170020726A1
· Labombarbe et al.
· 2017
[cited by applicant]
US 20170087100A1
· Scherer et al.
· 2017
[cited by applicant]
US 20170087101A1
· Scherer et al.
· 2017
[cited by applicant]
US 20170143832A1
· Günther et al.
· 2017
[cited by applicant]
US 20170216204A1
· Theisinger et al.
· 2017
[cited by applicant]
US 20170348285A1
· Hellstron
· 2017
[cited by applicant]
US 20180360908A1
· Beier et al.
· 2018
[cited by applicant]
US 20190328717A1
· Günther et al.
· 2019
[cited by applicant]
US 20190343793A1
· Günther et al.
· 2019
[cited by applicant]
US 20200023035A1
· Löscher
· 2020
[cited by applicant]
US 20200060987A1
· Gunther et al.
· 2020
[cited by applicant]
US 20200129543A1
· Löscher et al.
· 2020
[cited by applicant]
US 20200206241A1
· Theisinger et al.
· 2020
[cited by applicant]
US 20200246463A1
· Günther et al.
· 2020
[cited by applicant]
US 20200338015A1
· Scherer et al.
· 2020
[cited by applicant]
US 20210023166A1
· Löscher et al.
· 2021
[cited by applicant]
US 20210069014A1
· Löscher et al.
· 2021
[cited by applicant]
US 20210106558A1
· Löscher et al.
· 2021
[cited by applicant]
US 20210121471A1
· Löscher
· 2021
[cited by examiner]
US 20210236591A1
· Leo et al.
· 2021
[cited by applicant]
US 20210315832A1
· Scherer et al.
· 2021
[cited by applicant]
US 20210346313A1
· Beier et al.
· 2021
[cited by applicant]
US 20220008397A1
· Xu et al.
· 2022
[cited by applicant]
US 20220031844A1
· Mauden et al.
· 2022
[cited by applicant]
US 20220079925A1
· Günther et al.
· 2022
[cited by applicant]
US 20220226426A1
· Löscher et al.
· 2022
[cited by applicant]
US 20220354926A1
· Löscher et al.
· 2022
[cited by applicant]
US 20220362382A1
· Loscher et al.
· 2022
[cited by applicant]
US 20230139672A1
· Theisinger et al.
· 2023
[cited by applicant]
US 20230330056A1
· Günther et al.
· 2023
[cited by applicant]
US 20230398065A1
· Günther et al.
· 2023
[cited by applicant]
EP 0089815
· 1983
[cited by applicant]
EP 2708228A1
· 2014
[cited by applicant]
JP 2012250951
· 2012
[cited by applicant]
WO WO2002096432
· 2002
[cited by applicant]
WO WO2003088973
· 2003
[cited by applicant]
WO WO2003099258
· 2003
[cited by applicant]
WO WO2008136034
· 2008
[cited by applicant]
WO WO2008157614
· 2008
[cited by applicant]
WO WO2008157614A2
· 2008
[cited by examiner]
WO WO2010146536
· 2010
[cited by applicant]
WO 2011112669A1
· 2011
[cited by applicant]
WO WO2016063184
· 2016
[cited by applicant]
WO WO2016082644
· 2016
[cited by applicant]
WO 2018033854A1
· 2018
[cited by applicant]
Heiden et al. Investigative Ophthalmology & Visual Science Apr. 2014, vol. 55, 453. (Year: 2014).
[cited by examiner]
Kumar et al. J Adv Pharm Tech Res, 2011; 2(3):192-194. (Year: 2011).
[cited by examiner]
A. Sah et al. (2017), Artificial Cells, Nanomedicine, and Biotechnology, 45:3, 448-459, DOI: 10.3109/21691401.2016.1160917. (Year: 2017).
[cited by examiner]
Agrahari, V. et al., “A comprehensive insight on ocular pharmacokinetics,” Drug Delivery and Translational Research, vol. 6, No. 6, pp. 735-754, (2016).
[cited by applicant]
Ahmed, I. et al., “Disposition of Timolol and Inulin in the Rabbit Eye Following Corneal Versus Non-Corneal Absorption,” International Journal of Pharmaceutics, vol. 38, pp. 9-21, (1987).
[cited by applicant]
Agarwal, P. et al., “Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs,” International Journal of Pharmaceutics, vol. 538, No. 1-2, pp. 119-129, (2018).
[cited by applicant]
Bardin, L. et al., “Long-Range Nanometer-Scale Organization of Semifluorinated Alkane Monolayers at the Air/Water Interface,” Langmuir, vol. 27, pp. 13497-13505, (2011).
[cited by applicant]
Bertilla, S. et al., “Semifluorinated Alkanes as Stabilizing Agents of Fluorocarbon Emulsions,” Springer, vol. 12, 24 pages, (2005).
[cited by applicant]
Costa Gomes, M. et al., “Solubility of dioxygen in seven fluorinated liquids,” Journal of Fluorine Chemistry, vol. 125, pp. 1325-1329, (2004).
[cited by applicant]
Davies, N., “Biopharmaceutical Considerations in Topical Ocular Drug Delivery,” Clinical and Experimental Pharmacology and Physiology, vol. 27, pp. 558-562, (2000).
[cited by applicant]
Dembinski, R. et al., “Semi-fluorinated Alkanes as Carriers for Drug Targeting in Acute Respiratory Failure,” Experimental Lung Research, vol. 36, pp. 499-507, (2010).
[cited by applicant]
Deschamps, J. et al., “Solubility of oxygen, carbon dioxide and water in semifluorinated alkanes and in perfluorooctylbromide by molecular simulation,” Journal of Fluorine Chemistry, Elsevier, vol. 125, No. 3, (2004).
[cited by applicant]
Dias, A. et al., “Solubility of oxygen in liquid perfluorocarbons,” Fluid Phase Equilibria, vol. 222-223, pp. 325-330, (2004).
[cited by applicant]
Dutescu, R. et al., “Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, No. 1, 2 pages, (2014), Abstract Only.
[cited by applicant]
English-language machine translation of EP0670159 (A1) issued in U.S. Appl. No. 14/122,025 on Apr. 1, 2015, 10 pages.
[cited by applicant]
English-language machine translation of JP 2012-250951 (A), 13 pages.
[cited by applicant]
“Evo-Tears—Gebrauchsanweisung,” May 2015, retrieved from the Internet, date retrieved: Jun. 26, 2018, 2 pages, URL: http://video.aporot.de/docs/11213615.pdf.
[cited by applicant]
Freiburger Dokumentenserver (FreiDok), Albert-Ludwigs-Unversität Freiburg, retrieved from http://www.freidok.uni-freiburg.de/volltexte/5682/, retrieved on Feb. 5, 2014, 2 pages.
[cited by applicant]
Gehlsen. U. et al., “Cyclosporine A using F4H5 as liquid drug carrier is effective in treating experimental dry-eye disease,” Investigative Ophthalmology & Visual Science, vol. 56, No. 319, 2 pages, (2015), Abstract Onl…
[cited by applicant]
Gehlsen, U. et al., “A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye,” Graefe's Arch. Clin. Exp. Ophthalmol., vol. 25…
[cited by applicant]
Gehlsen, U. et al., “Omega-3 Fatty Acids Using F6H8-Carrier as Topical Therapy in Experimental Dry-Eye Disease,” Investigative Ophthalmology & Visual Science, vol. 57, p. 417, 1 page, (2016), Abstract Only.
[cited by applicant]
German, E. et al., “Reality of drop size from multi-dose eye drop bottles: is it cause for concern?” Eye, vol. 13, pp. 93-100, (1999).
[cited by applicant]
Hardung, H., “Semifluorierte und perfluorierte Verbindungen zur topischen und parenteralen Anwendung,” 2008, English Language Abstract, 2 pages, retrieved from https://freidok.uni-freiburg.de/data/5682 (retrieved on Jul…
[cited by applicant]
“Highlights of Prescribing Information: Zioptan,” pp. 1-11, (2014), https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202514s003s004lbl.pdf.
[cited by applicant]
Hoerauf, H. et al., “Combined Use of Partially Fluorinated Alkanes, Perfluorocarbon Liquids and Silicone Oil: An Experimental Study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 239, No. 5, pp. 37…
[cited by applicant]
Holm, R. et al., “A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs,” European Journal of Pharmaceutical Sciences, vol. 42, pp. 416-442, (2011).
[cited by applicant]
Kaercher, T. et al., “NovaTears® as new Therapy in Dry Eye Results from three prospective, multicenter, non-interventional studies in different patient populations,” TFOS Conference (Tear Film & Ocular Surface), Sep. 7-…
[cited by applicant]
Kociok, N. et al., “Influence on Membrane-Mediated Cell Activation by Vesicles of Silicone Oil or Perfluorohexyloctane,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, pp. 345-358, (2005).
[cited by applicant]
Kumar, S. et al., “Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment,” Journal of Advanced Pharmaceutical Technology & Research, vol. 2, No. 3, pp. 192-194, (2011).
[cited by applicant]
Lallemand, F. et al., “Cyclosporine A delivery to the eye: a pharmaceutical challenge,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 56, No. 3, 1 page, (2003), Abstract Only.
[cited by applicant]
“Latanoprost (Xalatan®),” Chemical Abstracts, CAS Registry No. 130209-82-4, retrieved from the Internet, date accessed: Mar. 21, 2022, 5 pages, URL:<https://www.chemicalbook.com/CASEN_130209-82-4.htm>.
[cited by applicant]
Lynch, M. et al., “Reduction of Phenylephrine Drop Size in Infants Achieves Equal Dilation With Decreased Systemic Absorption,” Arch Ophthalmol, vol. 105, 2 pages, (1987).
[cited by applicant]
Meinert, H. et al., “Semifluorinated Alkanes—A New Class of Compounds with Outstanding Properties for Use in Ophthalmology,” European Journal of Ophthalmology, vol. 10, No. 3, pp. 189-197, (2000).
[cited by applicant]
Messmer, E. et al., “Semifluorinated Alkanes as a Therapy for Meibomian Gland Dysfunction Results of a prospective, multi-centered observational study,” Presentation, DOG-Kongress, Sep. 29, 2016-Oct. 2, 2016, Berlin DOG…
[cited by applicant]
Messmer, E. et al., “Semifluorinated Alkanes as a Therapy for Meibomian Gland Dysfunction Results of a prospective, multi-centered observational study,” Presentation, DOG-Kongress, Sep. 29, 2016-Oct. 2, 2016, Berlin DOG…
[cited by applicant]
O'rourke, M. et al., “Enhancing Delivery of Topical Ocular Drops,” Cataract & Refractive Surgery Today Europe, 2 pages, (2016).
[cited by applicant]
Rathore, K. et al., “Timolol Maleate A Gold Standard Drug in Glaucoma Used as Ocular Films and Inserts: An Overview,” International Journal of Pharmaceutical Sciences Review and Research, vol. 3, No. 1, 8 pages, (2010).
[cited by applicant]
Santvliet, L. et al., “Determinants of Eye Drop Size,” Survey of Ophthalmology, vol. 49, No. 2, pp. 197-213, (2004).
[cited by applicant]
Scherer, D. et al., “Eyesol: A Novel Topical Ocular Drug Delivery System for Poorly Soluble Drugs,” Drug Development & Delivery, vol. 13, No. 1, pp. 40-44, (2013).
[cited by applicant]
“Semifluorinated alkane technology brings advantages for topical therapy,” Ophthalmology Times, 2016, pp. 1-2, http://www.ophthalmologytimes.com/ophthalmology/semifluorinated-alkane-technology-brings-advantages-topical-…
[cited by applicant]
Steven, P. et al., “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study,” Journal of Ocular Pharmacology and Therapeutics, vol. 31, No. 8, pp. 498-503, (2…
[cited by applicant]
Steven, P. et al., “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease,” Journal of Ocular Pharmacology and Therapeutics, vol. 33, No. 9, pp. 1-8, (2017).
[cited by applicant]
Steven, P. et al., “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study,” Investigative Ophthalmology & Visual Science, vol. 56, No. 4493, 1 page, (2015),…
[cited by applicant]
TIMOPTIC®, NDA 18-086/S-070 / NDA 18-086/S-072, Merck & Co, Inc, 11 pages, (2005).
[cited by applicant]
Van Der Heiden, H. et al., “Plasma and ocular pharmacokinetic study comparing 3 uL micro-drop to typical 40 μL drop volume of timolol 0.5% in pigmented rabbits,” ARVO Annual Meeting Abstract, Investigative Ophthalmology…
[cited by applicant]
Wong, D. et al., “Perfluorocarbons and Semifluorinated Alkanes,” Seminars in Ophthalmology, vol. 15, No. 1, pp. 25-35, (2000).
[cited by applicant]
Wirta, D. et al., “A Clinical Phase II Study to Assess Efficacy, Safety and Tolerability of Waterfree Cyclosporine Formulation for the Treatment of Dry Eye Disease,” Ophthalmology, vol. 126, pp. 792-800, (2019).
[cited by applicant]
“EvoTears, Product Description,” 2017, Accessed Online: Dec. 27, 2023, URL: https://evotears.com/at/das-produkt/.
[cited by applicant]
“Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol® in Adults with Moderate to Severe Dry Eye Disease,” Businesswire, Jan. 5, 2017, URL: <https://www.businesswire.com/ news/home/20…
[cited by applicant]
“Novaliq begins Phase 2 trial of Cyclasol for dry eye disease,” Optometry Times, vol. 8, No. 3, (2016), p. 24.
[cited by applicant]
“Novaliq GmbH Begins Phase II Clinical Trial of Cyclasol for the Treatment of Moderate to Severe Dry Eye Disease,” (online), 5 pages, (2016); retrieved on Jan. 8, 2021 from the Internet: https://www.biospace.com/article…
[cited by applicant]
“PharmaNews,” Kompass Ophthalmologie, vol. 2, No. 2, pp. 98-99, (2016).
[cited by applicant]
“Topical drug dosage forms for eye conditions,” The Pharmaceutical Journal, (Pharmaceutical Press, May 31, 2017), available at https://pharmaceutical-journal.com/article/Id/topical-drug-dosage-forms-for-eye-conditions.
[cited by applicant]
Ahmed, S. et al., “Ocular Drug Delivery: a Comprehensive Review,” AAPS PharmSciTech, vol. 24, No. 66, pp. 1-29, (2023).
[cited by applicant]
English language machine translation for “PharmaNews,” Kompass Ophthalmologie, vol. 2, No. 2, pp. 98-99, (2016).
[cited by applicant]
Majumdar, S. et al. “A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Eyedrop Suppresses Intraocular Inflammation in Experimental Models of Uveitis,” Current Molecular Medicine, vol. 17, No. 3, pp. 211-220…
[cited by applicant]
Meinert, H. et al., “The Use of Semifluorinated Alkanes in Blood-Substitutes,” Biomaterials, Artificial Cells, and Immobilization Biotechnology, vol. 21, No. 5, pp. 583-595, (1993).
[cited by applicant]
Sheppard, J. et al., “A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study,” Cornea, vol. 40, No. 10, pp. 1290-1297, (2021).
[cited by applicant]
Toris, C. et al., “Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction,” NIH Public Access, Author Manuscript, available in PMC 2009, 18 pages, front page states: Published in …
[cited by applicant]
Torkildsen, G. et al., “A Clinical Phase 2 Study to Assess Safety, Efficacy, and Tolerability of CyclASol for the Treatment of Dry Eye Disease,” Poster Presentation at American Academy of Ophthalmology (AAO), New Orlean…
[cited by applicant]